Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!
Update: 18. April 2005 The study is moving forward, albeit slowly. Dr. Andr? Galinowski has begun to contact volunteers individually, as he decides who fit the criteria. We are still looking for more volunteers and hope that you will be able to keep the study notice up on your site. best regard, Mr. Sutherland
Update: As of August 23rd 2004, this study has received a total of 13 interested volunteers. A few more are still needed, so if you are interested by all means please contact email@example.com.
First off, What is HPPD?
From DSM-IV R, "The handbook for the American Psychiatric Association"
292.89 Hallucinogen Persisting Perception Disorder The essential feature of Hallucinogen Persisting Perception Disorder (Flashbacks) is the transient recurrence of disturbances in perception thaat are reminescent of those experienced during one or more earlier Hallucinogen Intoxications. The person must have had no recent Hallucinogen Intoxication and must show no current drug toxicity (Criterion A). This reexperienceing of perceptual symptoms causes clinically significant distress or impairment in social, occupational, or other important areas of functioning (Criterion B). The symptoms are not due to a general medical condition (e.g., anatomical lesions and infections of the brain or visual epilepsies) and are not better accounted for by another mental disorder (e.g., delerium, dementia, or Schizophrenia) or by hypnopompic hallucinations (Criterion C). The perceptual disturbances may include geometric forms, peripheral-field images, flashes of color, intensified colors, trailing images (images left suspended in the path of a moving object as seen in stroboscopic photography), perceptions of entire objects, afterimages (a same-colored or complementary-colored "shadow" of an object remaining after the removal of the object), halos around objects, macropsia, and micropsia. The abnormal perceptions that are associated with Hallucinogen Persisting Perception Disorder occur episodically and may be self-induced (e.g., by thinking about them) or triggered by entry into a dark environment, various drugs, anxiety or fatigue, or other stressors. The episodes may abate after several months, but many persons report persisting episodes for 5 years or longer. Reality testing remains intact (i.e., the person realizes that the perception is a drug effect and does not represent external reality). In contrast, if the person has a delusional interpretation concerning the etiology of the perceptual disturbance, the appropriate diagnosis would be Psychotic Disorder Not Otherwise Specified.
Diagnostic criteria for 292.89 Hallucinogen Persisting Perception Disorder
A. The re-experiencing, following cesssation of use of a hallucinogen, of one or more of the perceptual symptoms that were experienced while intoxicated wiht the hallucinogen (e.g., geometric hallucinations, false perceptions of movement in the peripheral visual fields, flashes of colors, intensified colors, trails of images of moving objects, positive afterimages, halos around objects, macropsia, and micropsia.
B. The symptoms in Criterion A cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
C. The symptoms are not due to a general medical condition (e.g., anatomical lesions and infections of the brain, visual epilepsies) and are not better accounted for another mental disorder (e.g., delerium, dementia, Schizophrenia) or hypnopompic hallucinations.
To the point:
There is a specialist initiating a study for HPPD treatment in Paris, France. Participants must meet the following criteria:
Must be Diagnosed with HPPD.
Must not have experienced hallucinations before they first took a hallucinogenic drug.
Must not suffer from other non HPPD-related disorders.
Must not be currently taking any hallucinogenic drugs, including marijuana.
Must be less than 40 years of age.
Interested patients must first contact a Mr. Sutherland:
If selected, you will be contacted by the director of the study, Dr. Andr? Galinowski. You will have to come to Paris for at least two days (of your chosing). There is no compensation, but you will be contributing to a possible treatment for your disorder which could improve many lives.
The study will specifically include a functional MRI or PET scan conducted through Paris' Sainte Anne Hospital. Sainte Anne's is a European leader in brain imaging and hallucination treatment with non-invasive Transcranial Magnetic Stimulation (TMS). TMS has so far been successful in treating patients with auditory hallucinations with up to 80% success rates in some studies. The ultimate goal of this clinical research will be to explore the possibilities of TMS therapy for HPPD sufferers with distorted, hallucinatory vision. Please contact firstname.lastname@example.org if interested.